|
||||||||
|---|---|---|---|---|---|---|---|---|
| Basic information | ||||||||
| Chairman | President | Spokesperson | Telephone | Address | ESM Registration Date | |||
| Patrick Yuhmin Yang | Shih-Chia Hsiao | Yanda Lai | 02-2697-6100 | 17F.-12, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei CityTaipei,Taiwan | 2023/08/08 | |||
| Agent for litigious and non-litigious matters |
Tel of Agent for litigious and non-litigious matters |
Address of Agent for litigious and non-litigious matters |
||||||
| Shih-Chia Hsiao | 0226976100 | 17F.-12, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City | ||||||
| Industrycategory | Key businesses | |||||||
| Biotechnology and Medical Care | Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. | |||||||
| Market info | |
|---|---|
| Latest trading info | Historic trading info |
| Financial data | |||
|---|---|---|---|
| Cash flows statement | Item | ||
| Amount(NTD, in thousands) | |||
| Cash flows from operating activities | |||
| Cash flows from investing activities | |||
| Cash flows from financing activities | |||
| Consolidated/Individual balance sheet |
Current assets | ||
| Non-current assets | |||
| Total assets | |||
| Current liabilities | |||
| Non-current liabilities | |||
| Total liabilities | |||
| Share capital | |||
| Capital surplus | |||
| Retained earnings | |||
| Other equity interest | |||
| Treasury shares | |||
| Total equity attributable to owners of parent | |||
| Non-controlling interests | |||
| Total equity | |||
| Book Value per share(NT$) | |||
| Consolidated/Individual profit and loss statement |
Operating revenue | ||
| Operating costs | |||
| Gross profit from operations | |||
| Operating expenses | |||
| Net other income (expenses) | |||
| Net operating income | |||
| Non-operating income and expenses | |||
| Profit before tax | |||
| Tax expense | |||
| Profit from continuing operations | |||
| Profit from discontinued operations | |||
| Profit | |||
| Other comprehensive income | |||
| Comprehensive income | |||
| Basic earnings per share | |||
Auditor's report on latest financial statements： auditor's report：